UA116875C2 - Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять - Google Patents

Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять

Info

Publication number
UA116875C2
UA116875C2 UAA201405086A UAA201405086A UA116875C2 UA 116875 C2 UA116875 C2 UA 116875C2 UA A201405086 A UAA201405086 A UA A201405086A UA A201405086 A UAA201405086 A UA A201405086A UA 116875 C2 UA116875 C2 UA 116875C2
Authority
UA
Ukraine
Prior art keywords
polymorphs
herb2
arry
inhibitor
selective
Prior art date
Application number
UAA201405086A
Other languages
English (en)
Inventor
Дональд Т. КОРСОН
Крістофер М. Ліндеман
Даніел Дж. Ватсон
Original Assignee
Еррей Біофарма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еррей Біофарма Інк. filed Critical Еррей Біофарма Інк.
Publication of UA116875C2 publication Critical patent/UA116875C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

У цьому документі представлені поліморфи N4-(4-([1,2,4]триазоло[1,5-а]піридин-7-ілокси)-3-метилфеніл)-N6-(4,4-диметил-4,5-дигідрооксазол-2-іл)хіназолін-4,6-діаміну. Описані також способи одержання вказаних поліморфів і фармацевтичної композиції, що містить вказані поліморфи.
UAA201405086A 2011-10-14 2012-10-12 Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять UA116875C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547615P 2011-10-14 2011-10-14
US201261606185P 2012-03-02 2012-03-02
PCT/US2012/060138 WO2013056183A1 (en) 2011-10-14 2012-10-12 Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them

Publications (1)

Publication Number Publication Date
UA116875C2 true UA116875C2 (uk) 2018-05-25

Family

ID=47471982

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201405086A UA116875C2 (uk) 2011-10-14 2012-10-12 Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять

Country Status (17)

Country Link
US (6) US9168254B2 (uk)
EP (1) EP2766363A1 (uk)
JP (4) JP2014530243A (uk)
KR (2) KR102061917B1 (uk)
CN (1) CN104011047A (uk)
AU (1) AU2012323890A1 (uk)
BR (1) BR112014009084B1 (uk)
CA (1) CA2852060A1 (uk)
CL (1) CL2014000932A1 (uk)
CO (1) CO6960548A2 (uk)
CR (1) CR20140219A (uk)
IL (1) IL232062A0 (uk)
MX (2) MX370680B (uk)
RU (1) RU2629116C2 (uk)
SG (1) SG11201401460PA (uk)
UA (1) UA116875C2 (uk)
WO (1) WO2013056183A1 (uk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169072A (en) 2011-10-14 2019-02-12 Array Biopharma Inc Solid dispersions of a erb2 (her2) inhibitor
WO2013056183A1 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
CN109223791A (zh) * 2012-03-23 2019-01-18 阿雷生物药品公司 脑癌的治疗
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
MA49059A (fr) 2017-04-28 2021-03-24 Seagen Inc Traitement des cancers positifs à her2
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
KR20210146389A (ko) 2019-04-02 2021-12-03 어레이 바이오파마 인크. 단백질 티로신 포스파타제 억제제
JP2022553041A (ja) 2019-10-21 2022-12-21 シージェン インコーポレイテッド Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
JP2023502929A (ja) 2019-11-15 2023-01-26 シージェン インコーポレイテッド Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法
CA3183592A1 (en) 2020-05-29 2021-12-02 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
JP2023537676A (ja) 2020-07-29 2023-09-05 シージェン インコーポレイテッド トラスツズマブ、タキサン及びｖｅｇｆｒ－２アンタゴニストと組み合わせたツカチニブによりｈｅｒ２陽性癌を治療する方法
US20230391749A1 (en) * 2020-10-27 2023-12-07 Trevena, Inc. Crystalline and amorphous forms of a delta-opioid modulator

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2004264937B2 (en) 2003-08-14 2010-04-29 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
CA2539022A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DK1971601T3 (da) * 2005-11-15 2010-02-08 Array Biopharma Inc N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme
MY169072A (en) 2011-10-14 2019-02-12 Array Biopharma Inc Solid dispersions of a erb2 (her2) inhibitor
WO2013056183A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
CN109223791A (zh) 2012-03-23 2019-01-18 阿雷生物药品公司 脑癌的治疗

Also Published As

Publication number Publication date
US9168254B2 (en) 2015-10-27
AU2012323890A1 (en) 2014-05-29
JP2017128612A (ja) 2017-07-27
EP2766363A1 (en) 2014-08-20
CO6960548A2 (es) 2014-05-30
JP2014530243A (ja) 2014-11-17
US20180140603A1 (en) 2018-05-24
US9889134B2 (en) 2018-02-13
CL2014000932A1 (es) 2014-07-11
US11571424B2 (en) 2023-02-07
BR112014009084A2 (pt) 2017-05-09
CA2852060A1 (en) 2013-04-18
KR20200003245A (ko) 2020-01-08
US10765678B2 (en) 2020-09-08
US20190125749A1 (en) 2019-05-02
JP2018177822A (ja) 2018-11-15
US20230241066A1 (en) 2023-08-03
BR112014009084B1 (pt) 2021-09-21
KR102061917B1 (ko) 2020-01-02
RU2014119269A (ru) 2015-11-20
RU2629116C2 (ru) 2017-08-24
IL232062A0 (en) 2014-05-28
US20140243361A1 (en) 2014-08-28
US20160175309A1 (en) 2016-06-23
CR20140219A (es) 2014-07-11
CN104011047A (zh) 2014-08-27
MX2014004553A (es) 2015-02-12
WO2013056183A1 (en) 2013-04-18
KR20140082806A (ko) 2014-07-02
US10143692B2 (en) 2018-12-04
MX370680B (es) 2019-12-19
JP2016033166A (ja) 2016-03-10
SG11201401460PA (en) 2014-09-26
MX2019010083A (es) 2019-11-21
US20210077493A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
UA116875C2 (uk) Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
MY169072A (en) Solid dispersions of a erb2 (her2) inhibitor
IL266510B (en) History of aminopyrimidines, their preparation and pharmaceutical preparations containing them
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
MX349004B (es) Nuevos compuestos.
WO2013004995A8 (en) Pyrimidinone compounds and their use
WO2011086531A3 (en) New anti-malarial agents
PL2768937T3 (pl) Preparaty, ich zastosowanie jako środków do mycia naczyń lub do wytwarzania środków do mycia naczyń i ich wytwarzanie
WO2012021715A3 (en) Stable formulations of linaclotide
GB201118656D0 (en) New compounds
MX366899B (es) Nuevos compuestos.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
EP2861608B8 (en) Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
MX359288B (es) Forma iv del clorhidrato de ivabradina.
IL232701A (en) Pirazine compounds that inhibit sick kinase, pharmaceutical preparations that contain them and their use in the preparation of drugs
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2012107890A3 (en) Crystal forms of lurasidone chlorhydrate
WO2013155465A8 (en) Substituted xanthine derivatives
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
WO2011092564A3 (en) Process for the preparation of temsirolimus and its intermediates
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
IL218764A (en) Crystalline lupilopinic acid and the process for its preparation, its uses, and its pharmaceutical preparations
EP2789604A4 (en) DAZEZE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT AND METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF